CN104546939A - Application of dialister invisus in treating or preventing rheumatoid arthritis or related diseases - Google Patents
Application of dialister invisus in treating or preventing rheumatoid arthritis or related diseases Download PDFInfo
- Publication number
- CN104546939A CN104546939A CN201410522296.3A CN201410522296A CN104546939A CN 104546939 A CN104546939 A CN 104546939A CN 201410522296 A CN201410522296 A CN 201410522296A CN 104546939 A CN104546939 A CN 104546939A
- Authority
- CN
- China
- Prior art keywords
- alister
- bacterium
- muddiness
- wears
- dialister invisus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 53
- 241001624700 Dialister invisus Species 0.000 title claims abstract description 49
- 201000010099 disease Diseases 0.000 title claims abstract description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 40
- 235000013305 food Nutrition 0.000 claims abstract description 48
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 44
- 239000003814 drug Substances 0.000 claims abstract description 29
- 241000894006 Bacteria Species 0.000 claims description 78
- 239000007788 liquid Substances 0.000 claims description 20
- 239000002671 adjuvant Substances 0.000 claims description 19
- 241000281549 Dialister invisus DSM 15470 Species 0.000 claims description 16
- 239000000725 suspension Substances 0.000 claims description 13
- 239000001913 cellulose Substances 0.000 claims description 12
- 229920002678 cellulose Polymers 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 235000010489 acacia gum Nutrition 0.000 claims description 6
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 6
- 229940072056 alginate Drugs 0.000 claims description 6
- 235000010443 alginic acid Nutrition 0.000 claims description 6
- 229920000615 alginic acid Polymers 0.000 claims description 6
- 230000002421 anti-septic effect Effects 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000001506 calcium phosphate Substances 0.000 claims description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 6
- 235000011010 calcium phosphates Nutrition 0.000 claims description 6
- 235000012241 calcium silicate Nutrition 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- 235000010446 mineral oil Nutrition 0.000 claims description 6
- 239000002480 mineral oil Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 6
- 229960003415 propylparaben Drugs 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 235000013599 spices Nutrition 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 239000000454 talc Substances 0.000 claims description 6
- 235000012222 talc Nutrition 0.000 claims description 6
- 229910052623 talc Inorganic materials 0.000 claims description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 abstract description 29
- 208000024891 symptom Diseases 0.000 abstract description 27
- 206010003246 arthritis Diseases 0.000 abstract description 22
- 230000008961 swelling Effects 0.000 abstract description 14
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- 239000002068 microbial inoculum Substances 0.000 description 78
- 108090000623 proteins and genes Proteins 0.000 description 39
- 230000002917 arthritic effect Effects 0.000 description 38
- 230000000694 effects Effects 0.000 description 31
- 230000002265 prevention Effects 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 22
- 230000001580 bacterial effect Effects 0.000 description 15
- 241000894007 species Species 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 208000006558 Dental Calculus Diseases 0.000 description 11
- 206010015150 Erythema Diseases 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 239000003435 antirheumatic agent Substances 0.000 description 9
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 210000003296 saliva Anatomy 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000002550 fecal effect Effects 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007400 DNA extraction Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000002734 Collagen Type VI Human genes 0.000 description 2
- 108010043741 Collagen Type VI Proteins 0.000 description 2
- 238000011763 DBA/1J (JAX™ mouse strain) Methods 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 101150096372 1.3 gene Proteins 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- SOFPIAMTOZWXKT-UHFFFAOYSA-N 2h-1,2,4-triazine-3-thione Chemical compound SC1=NC=CN=N1 SOFPIAMTOZWXKT-UHFFFAOYSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010071155 Autoimmune arthritis Diseases 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940041022 streptomycins Drugs 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/15—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides an application of dialister invisus in treating or preventing rheumatoid arthritis or related diseases thereof, and also provides a pharmaceutical composition, a medicament, a food and a feed containing the dialister invisus. By providing the dialister invisus for animals, an anti-inflammatory effect can be effectively brought into play, the symptoms of rubefaction and swelling of joints can be effectively improved, and the symptoms of arthritis can be obviously relieved, so that the dialister invisus can be effectively used for treating or preventing the rheumatoid arthritis or the related diseases thereof.
Description
Technical field
The present invention relates to microbiological art, particularly, relate to muddiness and wear the purposes of Alister bacterium in treatment or prevention rheumatoid arthritis or its relevant disease, also relate to and comprise pharmaceutical composition, medicine, the food and feed that muddiness wears Alister bacterium.
Background technology
Rheumatoid arthritis (rheumatoid arthritis, RA) is called for short rheumatoid, is a kind of systemic autoimmune disease, mainly involves synovium of joint, is secondly the connective tissues such as serous coat, the heart, lung, blood vessel, nerve.Acute phase inflammatory main manifestations is synovial membrane angioedema, synovitis, if not by timely Diagnosis and Treat, acute inflammatory reaction disappears, and oozes out and absorbs gradually, and synovial membrane medium vessels nebula is formed, the remarkable hypertrophy of synovial cell.Then articular cartilage damage is caused, osseous tissue inflammation, necrosis and fibrous connective tissue hypertrophy.Calcification then occurs and occurs fibroid and bone arthrosclerosis, articular cavity is significantly narrow or disappear completely.The joint function disturbance that this phase chronic inflammation processes causes, is difficult to a great extent recover, can causes permanent disability.Just have 1 people to suffer from RA in every 100 ~ 150 people in the whole world, China's prevalence is 0.32% ~ 0.36%.RA all can fall ill at each age, was mainly in female middle-aged in adult, and the ratio of men and women is about 1:3.Within 2003, according to WHO, under good medical condition, medical expense is for each person every year about 6000 dollars, and the indirect loss caused by this disease also can not be ignored.
At present, doctor trained in Western medicine mainly adopts the method such as Drug therapy and gene therapy.Conventional Western medicine mainly contains NSAID (non-steroidal anti-inflammatory drug) (NSAIDs), glucocorticoid, makes medication, immunosuppressant and biological preparation etc. slowly.But price is high, toxic and side effects is larger shortcoming that Western medicine generally has, so limit their application.The selectivity of gene therapy is high, and it can be treated from molecular level for disease, simultaneously can by the long-term high-level local expression of repressor gene, and the treatment for RA patient opens new approach.But current gene therapy is also in the starting stage, still there is more problem.As lacked desirable carrier, different hosts produces different immunoreation to carrier, whether the gene of importing stably express etc. can all need further research and inquirement in body.In addition, the safety of gene therapy, medical expense and ethnics Problem etc. are also the problems that this research needs to solve.
Evidence suggests, enteric microorganism and systemic immunity are replied and RA exists certain contacting.Lactobacillus (lactic acid bacteria, LAB) can reduce pro-inflammatory cytokines level under the prerequisite not affecting regulating cell cytokines level, thus plays antiinflammatory action, alleviates RA symptom.Therefore can inferring, some treatment meanss that intestinal microecology is returned to normal, while recovery intestinal and function of immune system, also may play certain effect to alleviating RA symptom.Research confirms, a kind of LAB (Bacillus coagulans GBI-30,6086) may become a kind of ancillary drug alleviating RA symptom safely and efficiently
Because cause and onset of disease mechanism is not yet completely clear, though the treatment of RA obtains certain progress, be still in control or relief of symptoms stage so far, there is no effectively treatment or cure method.Therefore this area is a kind of effectively new in the urgent need to developing, and has no side effect, is used for the treatment of and prevents the medicine of rheumatoid arthritis and relevant disease thereof.
Summary of the invention
The present invention is intended to solve one of technical problem in correlation technique at least to a certain extent.For this reason, one object of the present invention is that proposing muddiness wears the purposes of Alister bacterium in treatment or prevention rheumatoid arthritis or its relevant disease.
In a first aspect of the present invention, the invention provides muddiness and wear Alister bacterium and preparing the purposes in medicine, described medicine is used for the treatment of or prevents rheumatoid arthritis or its relevant disease.Inventor finds, by providing this medicine to animal, effectively can play effect of antiinflammatory, the symptom of joint redness and swelling is effectively improved, and arthritic symptom obviously alleviates, and namely can effectively treat or prevent rheumatoid arthritis or its relevant disease.
According to embodiments of the invention, it is Dialister invisus that described muddiness wears Alister bacterium.Thereby, it is possible to effectively play effect for the treatment of or prevention rheumatoid arthritis or its relevant disease.
According to embodiments of the invention, it is be selected from least one in Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48 that described muddiness wears Alister bacterium.Thus, the effect for the treatment of or prevention rheumatoid arthritis or its relevant disease is better.
In a second aspect of the present invention, the invention provides a kind of pharmaceutical composition.According to embodiments of the invention, this pharmaceutical composition comprises: muddiness wears Alister bacterium; And pharmaceutically acceptable adjuvant.Inventor surprisingly finds, by providing this pharmaceutical composition to animal, can obviously suppress arthritic generation, joint redness and swelling are obviously gone down, arthritic symptom obviously alleviates, animal action is flexible, shows that rheumatoid arthritis or its relevant disease can effectively be treated or prevent to this pharmaceutical composition.
According to embodiments of the invention, it is Dialister invisus that described muddiness wears Alister bacterium.Thereby, it is possible to effectively play effect for the treatment of or prevention rheumatoid arthritis or its relevant disease.
According to embodiments of the invention, it is be selected from least one in Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48 that described muddiness wears Alister bacterium.Thus, the effect for the treatment of or prevention rheumatoid arthritis or its relevant disease is better.
According to embodiments of the invention, when described pharmaceutical composition is solid-state, described pharmaceutical composition comprises 1 × 10-1 × 10
20the described muddiness of cfu/g wears Alister bacterium, and when described pharmaceutical composition is in a liquid state, described pharmaceutical composition comprises 1 × 10-1 × 10
20the described muddiness of cfu/mL wears Alister bacterium.Thus, suppress arthritis to occur and improve the successful of arthritic symptom, if muddiness wears Alister, bacterial content is too low, the effect for the treatment of or prevention rheumatoid arthritis is undesirable, if muddiness wears Alister, bacterial content is too high, then treatment or prevention rheumatoid arthritis effect without significantly improving, cause waste.
According to a preferred embodiment of the present invention, when described pharmaceutical composition is solid-state, described pharmaceutical composition comprises 1 × 10
4-1 × 10
15the described muddiness of cfu/g wears Alister bacterium, and when described pharmaceutical composition is in a liquid state, described pharmaceutical composition comprises 1 × 10
4-1 × 10
15the described muddiness of cfu/mL wears Alister bacterium.
According to a further advantageous embodiment of the invention, when described pharmaceutical composition is solid-state, described pharmaceutical composition comprises 1 × 10
6-1 × 10
11cfu/g, described muddiness wear Alister bacterium, when described pharmaceutical composition is in a liquid state, described pharmaceutical composition comprises 1 × 10
6-1 × 10
11the described muddiness of cfu/mL wears Alister bacterium.
According to embodiments of the invention, described pharmaceutically acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.
According to embodiments of the invention, described pharmaceutically acceptable adjuvant is be selected from least one in lactose, glucose, sucrose, Sorbitol, mannose, starch, arabic gum, calcium phosphate, alginate, gelatin, calcium silicates, fine crystallization cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, nipasol, Talcum, magnesium stearate and mineral oil.
In a third aspect of the present invention, the invention provides a kind of medicine.According to embodiments of the invention, this medicine comprises: foregoing pharmaceutical composition.By providing this medicine to animal, can obviously suppress arthritic generation, joint redness and swelling are obviously gone down, and arthritic symptom obviously alleviates, and animal action is flexible, shows that rheumatoid arthritis or its relevant disease can effectively be treated or prevent to this medicine.
According to embodiments of the invention, described medicine is at least one dosage form be selected from granule, capsule, tablet, powder agent, oral liquid, suspension and Emulsion.Thus, be easy to carry out administration.
In a fourth aspect of the present invention, the invention provides a kind of food.According to embodiments of the invention, this food comprises: muddiness wears Alister bacterium; And acceptable adjuvant in bromatology.Inventor finds, by providing this food to animal, can obviously suppress arthritic generation, joint redness and swelling are obviously gone down, arthritic symptom obviously alleviates, and animal action is flexible, shows that rheumatoid arthritis or its relevant disease can effectively be treated or prevent to this food.
It should be noted that, the kind of term used in the present invention " food " is not particularly limited, and can be any known food, include but not limited to milk product, cookies, cake, beverage, health product etc.
According to embodiments of the invention, it is Dialister invisus that described muddiness wears Alister bacterium.Thereby, it is possible to effectively play effect for the treatment of or prevention rheumatoid arthritis or its relevant disease.
According to embodiments of the invention, it is be selected from least one in Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48 that described muddiness wears Alister bacterium.Thus, the effect for the treatment of or prevention rheumatoid arthritis or its relevant disease is better.
According to embodiments of the invention, when described food is solid-state, described food product packets is containing 1 × 10-1 × 10
20the described muddiness of cfu/g wears Alister bacterium, and when described food is in a liquid state, described food product packets is containing 1 × 10-1 × 10
20the described muddiness of cfu/mL wears Alister bacterium.Thus, suppress arthritis to occur and improve the successful of arthritic symptom, if muddiness wears Alister, bacterial content is too low, the effect for the treatment of or prevention rheumatoid arthritis is undesirable, if muddiness wears Alister, bacterial content is too high, then treatment or prevention rheumatoid arthritis effect without significantly improving, cause waste.
According to a preferred embodiment of the present invention, when described food is solid-state, described food product packets is containing 1 × 10
4-1 × 10
15the described muddiness of cfu/g wears Alister bacterium, and when described food is in a liquid state, described food product packets is containing 1 × 10
4-1 × 10
15the described muddiness of cfu/mL wears Alister bacterium.
According to a further advantageous embodiment of the invention, when described food is solid-state, described food product packets is containing 1 × 10
6-1 × 10
11cfu/g, described muddiness wear Alister bacterium, when described food is in a liquid state, described food product packets is containing 1 × 10
6-1 × 10
11the described muddiness of cfu/mL wears Alister bacterium.
According to embodiments of the invention, in described bromatology, acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.
According to embodiments of the invention, in described bromatology, acceptable adjuvant is be selected from least one in lactose, glucose, sucrose, Sorbitol, mannose, starch, arabic gum, calcium phosphate, alginate, gelatin, calcium silicates, fine crystallization cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, nipasol, Talcum, magnesium stearate and mineral oil.
According to embodiments of the invention, described food is at least one dosage form be selected from solid, milk, solution product, pulverulent product and suspension goods.
In a fifth aspect of the present invention, the invention provides a kind of feedstuff.According to embodiments of the invention, this feedstuff comprises: muddiness wears Alister bacterium.Inventor finds, by providing this feedstuff to animal, can obviously suppress arthritic generation, joint of animal is rubescent obviously to go down with swelling, arthritic symptom obviously alleviates, and animal action is flexible, shows that rheumatoid arthritis or its relevant disease can effectively be treated or prevent to this feedstuff.
According to embodiments of the invention, it is Dialister invisus that described muddiness wears Alister bacterium.Thereby, it is possible to effectively play effect for the treatment of or prevention rheumatoid arthritis or its relevant disease.
According to embodiments of the invention, it is be selected from least one in Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48 that described muddiness wears Alister bacterium.Thus, the effect for the treatment of or prevention rheumatoid arthritis or its relevant disease is better.
Should be understood that within the scope of the present invention, above-mentioned each technical characteristic of the present invention and can combining mutually between specifically described each technical characteristic in below (eg embodiment), thus form new or preferred technical scheme.As space is limited, tiredly no longer one by one to state at this.
Accompanying drawing explanation
Fig. 1 shows according to one embodiment of the invention, and what microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 were fallen ill on mouse arthritis affects Macroscopic score result;
Fig. 2 shows according to one embodiment of the invention, and microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 affect result to arthritic mice splenocyte in-vitro multiplication; And
Fig. 3 shows according to one embodiment of the invention, and microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 affect result to arthritic mice cytokine.
Detailed description of the invention
Below in conjunction with specific embodiment, set forth the present invention further.Should be understood that these embodiments are only not used in for illustration of the present invention to limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usual conveniently condition is as people such as Sambrook, molecular cloning: laboratory manual (New York:Cold Spring Harbor Laboratory Press, 1989) condition described in, or (James Cappuccino and Natalie Sherman compiles according to " microorganism: laboratory manual ", Pearson Education publishing house) described in condition, or according to the condition that manufacturer advises.
In a first aspect of the present invention, the invention provides muddiness and wear Alister bacterium and preparing the purposes in medicine, described medicine is used for the treatment of or prevents rheumatoid arthritis or its relevant disease.Inventor finds, by providing this medicine to animal, effectively can play effect of antiinflammatory, the symptom of joint redness and swelling is effectively improved, and arthritic symptom obviously alleviates, and namely can effectively treat or prevent rheumatoid arthritis or its relevant disease.
It should be noted that, term used herein " animal " is not particularly limited, and can be any animal with intestinal, preferred mammal, more preferably people, Lagomorpha or muroid.
According to embodiments of the invention, it is Dialister invisus that described muddiness wears Alister bacterium.Thereby, it is possible to effectively play effect for the treatment of or prevention rheumatoid arthritis or its relevant disease.
According to embodiments of the invention, it is be selected from least one in Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48 that described muddiness wears Alister bacterium.Thus, the effect for the treatment of or prevention rheumatoid arthritis or its relevant disease is better.
According to embodiments of the invention, animal subject forms arthritis model animal through modeling, animal pattern takes in Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48, all obviously can improve the rubescent and swelling situation of joint of animal, ameliorate osteoarthritis symptom.According to embodiments of the invention, respectively through arthritis DBA/1J mice that bacterial strain Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48 treat, with do not connect compared with subject matched group, joint redness and swelling are obviously disappeared, and arthritic symptom obviously alleviates.Thus, show that described bacterial strain can in order to prevention and therapy rheumatoid arthritis or its relevant disease.
In a second aspect of the present invention, the invention provides a kind of pharmaceutical composition.According to embodiments of the invention, this pharmaceutical composition comprises: muddiness wears Alister bacterium; And pharmaceutically acceptable adjuvant.Inventor surprisingly finds, by providing this pharmaceutical composition to animal, can obviously suppress arthritic generation, joint redness and swelling are obviously gone down, arthritic symptom obviously alleviates, animal action is flexible, shows that rheumatoid arthritis or its relevant disease can effectively be treated or prevent to this pharmaceutical composition.
According to embodiments of the invention, it is Dialister invisus that described muddiness wears Alister bacterium.Thereby, it is possible to effectively play effect for the treatment of or prevention rheumatoid arthritis or its relevant disease.
According to embodiments of the invention, it is be selected from least one in Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48 that described muddiness wears Alister bacterium.Thus, the effect for the treatment of or prevention rheumatoid arthritis or its relevant disease is better.
According to embodiments of the invention, when described pharmaceutical composition is solid-state, described pharmaceutical composition comprises 1 × 10-1 × 10
20the described muddiness of cfu/g wears Alister bacterium, and when described pharmaceutical composition is in a liquid state, described pharmaceutical composition comprises 1 × 10-1 × 10
20the described muddiness of cfu/mL wears Alister bacterium.Thus, suppress arthritis to occur and improve the successful of arthritic symptom, if muddiness wears Alister, bacterial content is too low, the effect for the treatment of or prevention rheumatoid arthritis is undesirable, if muddiness wears Alister, bacterial content is too high, then treatment or prevention rheumatoid arthritis effect without significantly improving, cause waste.
According to a preferred embodiment of the present invention, when described pharmaceutical composition is solid-state, described pharmaceutical composition comprises 1 × 10
4-1 × 10
15the described muddiness of cfu/g wears Alister bacterium, and when described pharmaceutical composition is in a liquid state, described pharmaceutical composition comprises 1 × 10
4-1 × 10
15the described muddiness of cfu/mL wears Alister bacterium.
According to a further advantageous embodiment of the invention, when described pharmaceutical composition is solid-state, described pharmaceutical composition comprises 1 × 10
6-1 × 10
11cfu/g, described muddiness wear Alister bacterium, when described pharmaceutical composition is in a liquid state, described pharmaceutical composition comprises 1 × 10
6-1 × 10
11the described muddiness of cfu/mL wears Alister bacterium.
According to embodiments of the invention, described pharmaceutically acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.
According to embodiments of the invention, described pharmaceutically acceptable adjuvant is be selected from least one in lactose, glucose, sucrose, Sorbitol, mannose, starch, arabic gum, calcium phosphate, alginate, gelatin, calcium silicates, fine crystallization cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, nipasol, Talcum, magnesium stearate and mineral oil.
In a third aspect of the present invention, the invention provides a kind of medicine.According to embodiments of the invention, this medicine comprises: foregoing pharmaceutical composition.By providing this medicine to animal, can obviously suppress arthritic generation, joint redness and swelling are obviously gone down, and arthritic symptom obviously alleviates, and animal action is flexible, shows that rheumatoid arthritis or its relevant disease can effectively be treated or prevent to this medicine.
According to embodiments of the invention, described medicine is at least one dosage form be selected from granule, capsule, tablet, powder agent, oral liquid, suspension and Emulsion.Thus, be easy to carry out administration.
In a fourth aspect of the present invention, the invention provides a kind of food.According to embodiments of the invention, this food comprises: muddiness wears Alister bacterium; And acceptable adjuvant in bromatology.Inventor finds, by providing this food to animal, can obviously suppress arthritic generation, joint redness and swelling are obviously gone down, arthritic symptom obviously alleviates, and animal action is flexible, shows that rheumatoid arthritis or its relevant disease can effectively be treated or prevent to this food.
It should be noted that, the kind of term used in the present invention " food " is not particularly limited, and can be any known food, include but not limited to milk product, cookies, cake, beverage, health product etc.
According to embodiments of the invention, it is Dialister invisus that described muddiness wears Alister bacterium.Thereby, it is possible to effectively play effect for the treatment of or prevention rheumatoid arthritis or its relevant disease.
According to embodiments of the invention, it is be selected from least one in Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48 that described muddiness wears Alister bacterium.Thus, the effect for the treatment of or prevention rheumatoid arthritis or its relevant disease is better.
According to embodiments of the invention, when described food is solid-state, described food product packets is containing 1 × 10-1 × 10
20the described muddiness of cfu/g wears Alister bacterium, and when described food is in a liquid state, described food product packets is containing 1 × 10-1 × 10
20the described muddiness of cfu/mL wears Alister bacterium.Thus, suppress arthritis to occur and improve the successful of arthritic symptom, if muddiness wears Alister, bacterial content is too low, the effect for the treatment of or prevention rheumatoid arthritis is undesirable, if muddiness wears Alister, bacterial content is too high, then treatment or prevention rheumatoid arthritis effect without significantly improving, cause waste.
According to a preferred embodiment of the present invention, when described food is solid-state, described food product packets is containing 1 × 10
4-1 × 10
15the described muddiness of cfu/g wears Alister bacterium, and when described food is in a liquid state, described food product packets is containing 1 × 10
4-1 × 10
15the described muddiness of cfu/mL wears Alister bacterium.
According to a further advantageous embodiment of the invention, when described food is solid-state, described food product packets is containing 1 × 10
6-1 × 10
11cfu/g, described muddiness wear Alister bacterium, when described food is in a liquid state, described food product packets is containing 1 × 10
6-1 × 10
11the described muddiness of cfu/mL wears Alister bacterium.
According to embodiments of the invention, in described bromatology, acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.
According to embodiments of the invention, in described bromatology, acceptable adjuvant is be selected from least one in lactose, glucose, sucrose, Sorbitol, mannose, starch, arabic gum, calcium phosphate, alginate, gelatin, calcium silicates, fine crystallization cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, nipasol, Talcum, magnesium stearate and mineral oil.
According to embodiments of the invention, described food is at least one dosage form be selected from solid, milk, solution product, pulverulent product and suspension goods.
In a fifth aspect of the present invention, the invention provides a kind of feedstuff.According to embodiments of the invention, this feedstuff comprises: muddiness wears Alister bacterium.Inventor finds, by providing this feedstuff to animal, can obviously suppress arthritic generation, joint of animal is rubescent obviously to go down with swelling, arthritic symptom obviously alleviates, and animal action is flexible, shows that rheumatoid arthritis or its relevant disease can effectively be treated or prevent to this feedstuff.
According to embodiments of the invention, it is Dialister invisus that described muddiness wears Alister bacterium.Thereby, it is possible to effectively play effect for the treatment of or prevention rheumatoid arthritis or its relevant disease.
According to embodiments of the invention, it is be selected from least one in Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48 that described muddiness wears Alister bacterium.Thus, the effect for the treatment of or prevention rheumatoid arthritis or its relevant disease is better.
According to embodiments of the invention, when described feedstuff is solid-state, described feedstuff comprises 1 × 10-1 × 10
20the described muddiness of cfu/g wears Alister bacterium, and when described feedstuff is in a liquid state, described feedstuff comprises 1 × 10-1 × 10
20the described muddiness of cfu/mL wears Alister bacterium.Thus, suppress arthritis to occur and improve the successful of arthritic symptom, if muddiness wears Alister, bacterial content is too low, the effect for the treatment of or prevention rheumatoid arthritis is undesirable, if muddiness wears Alister, bacterial content is too high, then treatment or prevention rheumatoid arthritis effect without significantly improving, cause waste.
According to a preferred embodiment of the present invention, when described feedstuff is solid-state, described feedstuff comprises 1 × 10
4-1 × 10
15the described muddiness of cfu/g wears Alister bacterium, and when described feedstuff is in a liquid state, described feedstuff comprises 1 × 10
4-1 × 10
15the described muddiness of cfu/mL wears Alister bacterium.
According to a further advantageous embodiment of the invention, when described feedstuff is solid-state, described feedstuff comprises 1 × 10
6-1 × 10
11cfu/g, described muddiness wear Alister bacterium, when described feedstuff is in a liquid state, described feedstuff comprises 1 × 10
6-1 × 10
11the described muddiness of cfu/mL wears Alister bacterium.
Embodiment 1 determines the probiotics treating or prevent rheumatoid arthritis
1.1 sample collections and DNA extraction
Collect the feces of 212 volunteers, tartar and saliva sample altogether from BJ Union Hospital, sample message, in table 1, wherein, is divided into training group and test group.Training group comprises 157 volunteers, and wherein 77 is the RA case of not treating, and 80 is healthy person (contrast).In test group, wherein 34 volunteers to form 17 " case-health " right, wherein have 8 to having relationship by blood, other 9 to not having blood relationship; Other 21 volunteers are that DMARD (disease-modifying antirheumatic drugs) treats RA case.
Refrigeration transportation after gathering fecal specimens also transfers to rapidly-80 DEG C of preservations, carry out DNA extraction (with reference to Qin, J.et al.A metagenome-wide association study of gut microbiota in type 2 diabetes.Nature 490,55 – 60 (2012)).When gathering tartar sample, utilize medical calm from the tartar of dental surface scraping 3 μ l, be transferred to 200 μ l 1x lysis buffer (10mM Tris, 1mM EDTA, 0.5% polysorbas20,200 μ g/ml E.C. 3.4.21.64s) in, cultivate 2 hours at 55 DEG C, then cultivate 10 minutes at 95 DEG C, stop lytic response, finally in-80 DEG C of preservations.When gathering saliva sample, get 100 μ l samples in the collecting pipe containing 100 μ l 2x lysis buffers, meanwhile, scraping posterior phraynx surface sample also adds in this pipe, and follow-up cleavage step is identical with tartar sample, equally in-80 DEG C of preservations.Tartar sample and saliva sample to BGI-Shenzhen, carry out DNA extraction with reference to fecal specimens through refrigeration transportation.
When volunteer is admitted to hospital first, collect phenotypic information according to standardization program.The fecal specimens of 21 DMARD treatment cases is only included among 212 fecal specimens for building enteric microorganism gene set, no longer analyzes herein.This research obtains BJ Union Hospital and BGI-Shenzhen's Institutional Review Board approval.
Table 1 sample message
1.2 grand gene order-checking and assemblings
Utilize the DNA sample extracted to build sequencing library, on Illumina checks order platform, carry out two-way (Paired-end) grand gene order-checking (Insert Fragment 350bp reads long 100bp).(quality-controlled is filtered to the data that order-checking produces, remove adapter polluted sequence, go low quality sequence and remove host genome polluted sequence), and utilize SOAPdenovo software (v2.04) to carry out accent assembling.
It is 0.37%, 5.55% and 40.85% respectively that the average host genome of feces, tartar and saliva sample is polluted.
1.3 gene sets build
For the assembling fragment (contigs) assembled, GeneMark software (v2.7d) is utilized to carry out predictive genes, then (alignment similarity (identity) is more than 95% to utilize BLAT software to carry out de-redundancy, the coverage (overlap) of comparison is more than 90%, there is no breach (gaps)), for 212 fecal specimens (treating sample comprising 21 DMARD), obtain and comprise 3, the nonredundancy gene set of 800,011 gene; For 203 buccal sample (comprising 105 tartar samples and 98 saliva samples), obtain and comprise 3,234, the nonredundancy gene set of 997 genes.(alignment similarity is more than 95% with reference in gene set to utilize BLAT software fecal specimens gene set to be added to further the published enteric microorganism comprising more than 430 ten thousand genes, comparison coverage is more than 90%, with reference to above-mentioned document Qin, J.et al.2012), finally obtain the new gene collection comprising more than 590 ten thousand genes.
High-quality sequenced fragments (reads) and intestinal or oral cavity are compared with reference to gene set, thus obtains the relative abundance (with reference to above-mentioned document Qin, J.et al.2012) of gene.
1.4 species taxonomy annotations calculate with abundance
By comparing with IMG (v400) data base, species taxonomy is carried out (with reference to above-mentioned document Qin to the gene of prediction, J.et al.2012), (alignment similarity is more than 65% to obtain the species taxonomy of a level respectively, comparison coverage is more than 70%), belong to the species taxonomy (alignment similarity is more than 85%) of level and the species taxonomy (alignment similarity is more than 95%) of the level of kind.The relative abundance of gene is utilized to calculate the relative abundance of these species (with reference to above-mentioned document Qin, J.etal.2012), and carry out statistical test (p<0.05) with rank test (Wilcoxon rank-sum test), there are the species of significant difference in the relative abundance between determining case and contrasting.
1.5 grand genome association analyses
By comparing case and the fecal microorganism gene set (microbiome) contrasted, 3, (each gene at least appears in 6 samples 110,085 gene, sample n=157, case is not treated containing 21 DMARD described in table 1) in, find that the relative abundance of 83,858 genes has significant difference (p<0.01, rank test, FDR=0.3285), these genes are marker gene.According to these marker gene relative abundance difference in the sample to which, further cluster, obtains grand genome linkage group (the Metagenomic Linkage Group of feces, MLG, a MLG is similar to species, and clustering method is with reference to above-mentioned document Qin, J.et al.2012).Same method, from 2 of tartar, in 247,835 genes (each gene at least appears in 6 samples, sample n=105), filter out 209,820 marker gene (p<0.01, rank test, FDR=0.072), cluster, obtains the MLG of tartar.From 2,404 of saliva, in 726 genes (each gene at least appears in 6 samples, sample n=98), filter out 206,399 marker gene (p<0.01, rank tests, FDR=0.088), cluster, obtains saliva MLG.In addition, by comparing the fecal microorganism gene before and after DMARD treatment, from 1, in 538,688 genes (each gene at least appears in 6 samples, sample n=64), filter out 86158 marker gene (p<0.05, paired Wilcoxon rank-sum test, FDR=0.912), cluster is treated in the feces MLGs of case to DMARD.
According to classification and the relative abundance of MLGs constitutivegene, carry out MLGs species taxonomy and build MLGs relative abundance spectrum (with reference to above-mentioned document Qin, J.et al.2012).To the level to be categorized into kind, in demand fulfillment MLGs 90% gene can comparison to (, more than 95%, comparison coverage is more than 70% for alignment similarity) on the genome of these species.To be categorized into genus level, then needing the gene of in MLGs 80%, no matter being at DNA sequence or protein sequence, being all higher than 80% with the similarity of this genus.According to Kendall ' the s dependency (regardless of case-control status) between all samples abundance, MLGs can be carried out cluster further.Intestinal MLG, saliva MLG, tartar MLG with DMARD treat the species taxonomy result of relevant MLG respectively in table 2, table 3, table 4, table 5.
The species taxonomy information of table 2 intestinal MLG
The species taxonomy information of table 3 saliva MLG
The species taxonomy information of table 4 tartar MLG
Table 5 DMARD treats the species taxonomy information of relevant MLG
Embodiment 2 zoopery is verified
In order to verify that embodiment 1 is determined treatment at table 2, table 3, table 4, table 5 or prevented the probiotics of rheumatoid arthritis, inventor carries out zoopery to each strain, utilizes its effect of the obtainable host strains of this strain.
Experimental technique
1. modeling and administration
The male DBA/1J mice of SPF (Specific pathogen free) level in 6 ~ 8 week age, be purchased from Chinese Academy of Sciences's Shanghai Experimental Animal Center, raise in IVC (individual ventilated cage) mouse cage system (purchased from Suzhou Feng Shi laboratory animal equipment company limited), indoor maintenance temperature 22 ~ 24 DEG C, humidity 40% ~ 60%, illumination every day 12h, ad lib and drinking-water.Adaptability is divided into after raising 2 weeks 5 groups (model control group, microbial inoculum 1 group, microbial inoculum 2 groups, microbial inoculum 3 groups, Normal groups) at random, often organizes 12.Dialister invisus DSM 15470 (microbial inoculum 1) is purchased from DSM (Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH); Dialister invisus E2.20 (microbial inoculum 2) and Dialister invisus E9.48 (microbial inoculum 3) all derives from dentistry institute microorganism section of Gai Shi hospital of London King's College (Department of Microbiology, Dental Institute, Guy's Tower, Guy's Hospital, King's College London, UK).In kitchen meat culture fluid (DSMZ Medium 78), 37 DEG C of Anaerobic culturel 2 ~ 3 days, through 16S rDNA check order qualification errorless after start experiment.Bacterial strain information is in table 6.
Table 6 bacterial strain information
| Numbering | Strain name |
| Microbial inoculum 1 | Dialister invisus DSM 15470 |
| Microbial inoculum 2 | Dialister invisus E2.20 |
| Microbial inoculum 3 | Dialister invisus E9.48 |
With reference to the method (S.Yoshino of S.Yoshino, E.Sasatomi, M.Ohsawa, Bacterial lipopolysaccharide acts as an adjuvant to induce autoimmune arthritis in mice, 2000) modeling method, in brief:
From experiment the 1st day, microbial inoculum 1 group (microbial inoculum 1+CIA/LPS), microbial inoculum 2 groups (microbial inoculum 2+CIA/LPS), microbial inoculum 3 groups (microbial inoculum 3+CIA/LPS) respectively with 500 μ l/50g.BW dosage, gavage bacterium 1, bacterium 2, bacterium 3 fresh medium (10
9-10
10cfu/ml), model control group (M+CIA/LPS) and Normal group (M+AA+PBS) be gavage equal-volume aseptic culture fluid respectively, administration every other day 28 days.At the 1st day, the 21st day, II Collagen Type VI (CIA) is utilized to induce the generation of 3 model group (microbial inoculum 1 group, microbial inoculum 2 groups and microbial inoculum 3 groups) and model control group mouse arthritis in conjunction with lipopolysaccharide (LPS).Concrete operations are: 100mg II collagen type (taking from calf articular cartilage, Funakoshi Co) is dissolved in 100ml 5mM acetic acid (AA), and 4 DEG C of stirrings are spent the night, intraperitoneal injection of mice.Get lipopolysaccharide (Shanghai Vaccine and Serum Institute) the 1 μ g of E.coli 011:B4 subsequently, be dissolved in 0.1ml phosphate buffer (PBS), equally through intraperitoneal injection.Normal group selects 5mM acetic acid through same volume and PBS buffer lumbar injection at same time.Observe mice foot claw-like state every day, weekly arthritis index is marked.Start latter 35 days in experiment, often organize random selecting 6 execution, get spleen cell and carry out subsequent experimental.Residue mice continues to observe course of arthritis progress and 50 days cervical dislocation are put to death after experiment starts.
2. arthritis evaluations
Utilize naked eyes to carry out Macroscopic score according to the increase of erythema and periarticular tissue edema situation to the arthritic order of severity and obtain arthritis index, concrete standards of grading are described below: 0: do not have arthritic sign; 1:1 arthroncus and/or rubescent; 2:2 arthroncus and/or rubescent; 3: be greater than 2 arthroncuss and/or rubescent; 4: whole sufficient pawl generation severe joint inflammation.Every mouse arthritis index is every animal 4 pawl score sum.
3. microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 are on the impact of Collagen-Induced Arthritis mouse boosting cell in-vitro multiplication
Random selecting model group (microbial inoculum 1 group, microbial inoculum 2 groups and microbial inoculum 3 groups), model control group and Normal group often organize each 6 mices, conventional separating Morr. cell.(Sailongbone extracts is to the therapeutical effect of the mouse arthritis that cattle II Collagen Type VI is induced and Mechanism Study for the method for subsequent operation reference Zhao Xiaohui etc., Zhao Xiaohui, Yue Huilan, Mei Lijuan, Shao Zan, Tao Yanduo, in May, 2008): with the RPMI RPMI-1640 containing 10% calf serum by cell concentration furnishing 4 × 10
6cell/ml.In 96 orifice plates, every hole adds 100 μ l cell suspension, 100 μ l collagen protein antigens.Cell is in containing 5%CO
237 DEG C of incubators in cultivate, cultivate and terminate the every hole of front 8h and add 25 μ l
3h-thymidylic acid.Continue to be cultured to experiment to terminate.With cell collector by cell harvesting on glass fibre membrane, read in cell DNA on β calculating instrument after adding scintillation solution
3h-thymidylic acid amount, represents cell proliferative conditions with umber of pulse per minute (counts per minute, cpm).
4. microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 are on the impact of arthritic mice inflammatory cytokine
Conventional method separating Morr. cell, with the RPMI RPMI-1640 containing 10% calf serum by cell concentration furnishing 4 × 10
6cell/ml, is inoculated in 24 hole tissue culturing plates with splenocyte suspension 1ml/ hole, wherein containing 1 mM glutamine, and 100 U/ml penicillins, 100 mg/ml streptomycins, 5 × 10
-5m 2 mercapto ethanol and 1% hot deactivation autoserum.After 48h, collect supernatant in-70 DEG C of preservations, utilize ELISA kit (being purchased from Mei Lian bio tech ltd, Shanghai) to detect wherein cytokine IL-12, IFN-γ, TNF-α and IL-10 level.
Experimental result
1. microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 impact that mouse arthritis is fallen ill.
Microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 Macroscopic score on the impact that mouse arthritis is fallen ill the results are shown in Table 7 and Fig. 1.From experimental result, microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 administration, after 4 weeks, compare model control group, and obviously can suppress the generation of CIA mouse arthritis, mice foot swelling is obviously gone down, and arthritic symptom obviously alleviates, and mice action is more flexible.
What table 7 microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 were fallen ill on mouse arthritis affects result (often organizing 6 mices)
2. microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 are on the impact of arthritic mice splenocyte in-vitro multiplication
The impact on arthritic mice splenocyte in-vitro multiplication of microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 the results are shown in Table 8 and Fig. 2, wherein, represent that between two groups, numerical value is not through Tukey ' s Test checkout discrepancy significantly (p>0.05) with same letter mark.As seen from the experiment, by gavaging microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3, when adding antigen, the external breeder reaction after antigenic stimulus of arthritic mice splenocyte obvious reduction compared with model control group, under the condition not adding antigen, each model group also show Spleen cell proliferation inhibitory action in various degree.
Table 8 microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 are on the impact (often organizing 6 mices) of arthritic mice splenocyte in-vitro multiplication
3. microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 are on the impact of arthritic mice cytokine
Microbial inoculum 1, microbial inoculum 2 and the impact of microbial inoculum 3 on arthritic mice cytokine the results are shown in Table 9 and Fig. 3, and wherein, between the expression two groups of same letter mark, numerical value is not through Tukey ' s Test checkout discrepancy significantly (p>0.05).From experimental result, detect can find by ELISA, compare with Normal group, 3 model group mouse cells press down scorching factor IL-10 and secrete significantly minimizing (p<0.05), inflammatory factor IL-12 and TNF-α secretion significantly increases (p<0.05), and inflammatory factor IFN-γ secretion does not have significant change (p>0.05); Compare with model control group, model group mouse cell IL-10 secretion significantly increases (p<0.05), IL-12, IFN-γ, TNF-α secretes and significantly reduces (p<0.05), and without significant difference (p>0.05) between 3 model group.Illustrate that microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 gavage can suppress the secretion of inflammatory factor IL-12, IFN-γ, TNF-α in spleen cell cultures supernatant, and improving the secretion pressing down scorching factor IL-10, display microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 pairs of arthritic mice cell immunity of spleen hyperfunctioning have obvious inhibitory action.。
Table 9 microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 are on the impact (often organizing 6 mices) of arthritic mice cytokine
Conclusion
The above results shows, on CIA mice model of rheumatoid arthritis, microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 obviously can suppress the morbidity of mouse arthritis, alleviate the related symptoms of CIA mice, demonstrate good antiinflammatory action.
In the description of this description, specific features, structure, material or feature that the description of reference term " embodiment ", " some embodiments ", " example ", " concrete example " or " some examples " etc. means to describe in conjunction with this embodiment or example are contained at least one embodiment of the present invention or example.In this manual, to the schematic representation of above-mentioned term not must for be identical embodiment or example.And the specific features of description, structure, material or feature can combine in one or more embodiment in office or example in an appropriate manner.In addition, when not conflicting, the feature of the different embodiment described in this description or example and different embodiment or example can carry out combining and combining by those skilled in the art.
Although illustrate and describe embodiments of the invention above, be understandable that, above-described embodiment is exemplary, can not be interpreted as limitation of the present invention, and those of ordinary skill in the art can change above-described embodiment within the scope of the invention, revises, replace and modification.
Claims (10)
1. muddiness is worn Alister bacterium and is being prepared the purposes in medicine, and described medicine is used for the treatment of or prevents rheumatoid arthritis or its relevant disease,
Optionally, it is Dialister invisus that described muddiness wears Alister bacterium,
Optionally, described muddiness wears Alister bacterium is be selected from least one in Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48.
2. a pharmaceutical composition, is characterized in that, comprising:
Muddiness wears Alister bacterium; And
Pharmaceutically acceptable adjuvant,
Optionally, it is Dialister invisus that described muddiness wears Alister bacterium,
Optionally, described muddiness wears Alister bacterium is be selected from least one in Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48.
3. pharmaceutical composition according to claim 2, is characterized in that, when described pharmaceutical composition is solid-state, described pharmaceutical composition comprises 1 × 10-1 × 10
20cfu/g, preferably 1 × 10
4-1 × 10
15cfu/g, more preferably 1 × 10
6-1 × 10
11the described muddiness of cfu/g wears Alister bacterium,
When described pharmaceutical composition is in a liquid state, described pharmaceutical composition comprises 1 × 10-1 × 10
20cfu/mL, preferably 1 × 10
4-1 × 10
15cfu/mL, more preferably 1 × 10
6-1 × 10
11the described muddiness of cfu/mL wears Alister bacterium.
4. pharmaceutical composition according to claim 2, it is characterized in that, described pharmaceutically acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice
Optionally, described pharmaceutically acceptable adjuvant is be selected from least one in lactose, glucose, sucrose, Sorbitol, mannose, starch, arabic gum, calcium phosphate, alginate, gelatin, calcium silicates, fine crystallization cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, nipasol, Talcum, magnesium stearate and mineral oil.
5. a medicine, is characterized in that, comprising:
Pharmaceutical composition according to any one of claim 2-4.
6. medicine according to claim 5, is characterized in that, described medicine is at least one dosage form be selected from granule, capsule, tablet, powder agent, oral liquid, suspension and Emulsion.
7. a food, is characterized in that, comprising:
Muddiness wears Alister bacterium; And
Acceptable adjuvant in bromatology,
Optionally, it is Dialister invisus that described muddiness wears Alister bacterium,
Optionally, described muddiness wears Alister bacterium is be selected from least one in Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48.
8. food according to claim 7, is characterized in that, when described food is solid-state, described food product packets is containing 1 × 10-1 × 10
20cfu/g, preferably 1 × 10
4-1 × 10
15cfu/g, more preferably 1 × 10
6-1 × 10
11cfu/g, described muddiness wear Alister bacterium,
When described food is in a liquid state, described food product packets is containing 1 × 10-1 × 10
20cfu/mL, preferably 1 × 10
4-1 × 10
15cfu/mL, more preferably 1 × 10
6-1 × 10
11the described muddiness of cfu/mL wears Alister bacterium.
9. food according to claim 7, it is characterized in that, in described bromatology, acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice
Optionally, in described bromatology, acceptable adjuvant is be selected from least one in lactose, glucose, sucrose, Sorbitol, mannose, starch, arabic gum, calcium phosphate, alginate, gelatin, calcium silicates, fine crystallization cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, nipasol, Talcum, magnesium stearate and mineral oil
Optionally, described food is at least one dosage form be selected from solid, milk, solution product, pulverulent product and suspension goods.
10. a feedstuff, is characterized in that, comprising: muddiness wears Alister bacterium,
Optionally, it is Dialister invisus that described muddiness wears Alister bacterium,
Optionally, described muddiness wears Alister bacterium is be selected from least one in Dialister invisus DSM 15470, Dialister invisus E2.20 and Dialister invisus E9.48.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410522296.3A CN104546939B (en) | 2014-09-30 | 2014-09-30 | Muddiness wears Alister bacterium and is treating or preventing the application in rheumatoid arthritis |
| HK15110165.1A HK1209357A1 (en) | 2014-09-30 | 2015-10-16 | Use of dialister invisus in the treatment or prevention of rheumatoid arthritis or related diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410522296.3A CN104546939B (en) | 2014-09-30 | 2014-09-30 | Muddiness wears Alister bacterium and is treating or preventing the application in rheumatoid arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104546939A true CN104546939A (en) | 2015-04-29 |
| CN104546939B CN104546939B (en) | 2019-02-01 |
Family
ID=53064711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410522296.3A Active CN104546939B (en) | 2014-09-30 | 2014-09-30 | Muddiness wears Alister bacterium and is treating or preventing the application in rheumatoid arthritis |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN104546939B (en) |
| HK (1) | HK1209357A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017109059A1 (en) * | 2015-12-22 | 2017-06-29 | Vib Vzw | Microbial marker in inflammatory arthritis diseases |
| WO2017220802A1 (en) | 2016-06-23 | 2017-12-28 | Vib Vzw | Means and methods to treat inflammation-associated disorders or conditions |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013037068A1 (en) * | 2011-09-14 | 2013-03-21 | Queen's University At Kingston | Method for treatment of disorders of the gastrointestinal system |
-
2014
- 2014-09-30 CN CN201410522296.3A patent/CN104546939B/en active Active
-
2015
- 2015-10-16 HK HK15110165.1A patent/HK1209357A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013037068A1 (en) * | 2011-09-14 | 2013-03-21 | Queen's University At Kingston | Method for treatment of disorders of the gastrointestinal system |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017109059A1 (en) * | 2015-12-22 | 2017-06-29 | Vib Vzw | Microbial marker in inflammatory arthritis diseases |
| WO2017220802A1 (en) | 2016-06-23 | 2017-12-28 | Vib Vzw | Means and methods to treat inflammation-associated disorders or conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1209357A1 (en) | 2016-04-01 |
| CN104546939B (en) | 2019-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104546940A (en) | Application of common bacteroides in treatment or prevention of rheumatoid arthritis or related diseases thereof | |
| CN104546935A (en) | Application of bacteroides thetaiotaomicron in treating or preventing rheumatoid arthritis or related diseases thereof | |
| CN104546942A (en) | Application of bacteroides dorei in treating or preventing rheumatoid arthritis or related diseases thereof | |
| CN104546934A (en) | Application of parabacteroides merdae in treating or preventing rheumatoid arthritis or related diseases | |
| CN104546932A (en) | Application of bacteroides ovatus in treating or preventing rheumatoid arthritis or related diseases thereof | |
| CN104546933A (en) | Application of bacteroides caccae in treatment or prevention of rheumatoid arthritis or related diseases thereof | |
| CN107847529B (en) | Compositions comprising bacterial strains | |
| CN102115721B (en) | Lactobacillus isolated strains with anti-inflammatory activity and use thereof | |
| CN104546945A (en) | Application of bifidobacterium bifidum in treating or preventing rheumatoid arthritis or related diseases thereof | |
| US7344867B2 (en) | Selection and use of lactic acid bacteria for reducing inflammation in mammals | |
| CN101575582A (en) | Lactobacillus separation strains with anti-inflammatory activity and application thereof | |
| CN104546930B (en) | Haemophilus parainfluenzae is treating or preventing the application in rheumatoid arthritis or its related disease | |
| TW200944215A (en) | Lactobacillus isolates having anti-inflammatory activities and uses of the same | |
| Mattarelli et al. | The Bifidobacteria and related organisms: biology, taxonomy, applications | |
| EP2189521B1 (en) | Method of obtaining lactic acid bacteria and their cellular components inducing immunoregulatory function | |
| CN104546938B (en) | Extremely huge Megamonas is treating or preventing the application in rheumatoid arthritis | |
| Darilmaz et al. | Influence of gastrointestinal system conditions on adhesion of exopolysaccharide-producing Lactobacillus delbrueckii subsp. bulgaricus strains to caco-2 cells | |
| CN104546947A (en) | Application of lactobacillus crispatus in treating or preventing rheumatoid arthritis or related diseases | |
| CN104546944B (en) | Lactococcus lactis is treating or preventing the application in rheumatoid arthritis or its related disease | |
| CN104546939A (en) | Application of dialister invisus in treating or preventing rheumatoid arthritis or related diseases | |
| EP3641796A1 (en) | Therapeutic uses of lactobacillus plantarum | |
| CN102781466B (en) | The probiotic bifidobacterium compositions conformed to secretor blood group state | |
| CN104546936B (en) | Fleck melaninogenicus is treating or preventing the application in rheumatoid arthritis | |
| CN104546943A (en) | Application of alistipes shahii in treating or preventing rheumatoid arthritis or related diseases | |
| CN104546937B (en) | Clostridium nexile is treating or preventing the application in rheumatoid arthritis or its related disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1209357 Country of ref document: HK |
|
| CB02 | Change of applicant information |
Address after: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Applicant after: BGI-Shenzhen Co., Ltd. Applicant after: Shenzhen Huada Academy of life science Address before: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Applicant before: BGI-Shenzhen Co., Ltd. Applicant before: BGI-Shenzhen |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |